A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is at least 6-weeks postpartum at the time of administration of study drug, following the delivery of a healthy singleton neonate * Is willing and able to express breast milk using an electric pump prior to study drug administration and is expected to be able to express at least 4 times over a 24-hour period after study drug administration Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, psychiatric, or major neurological (including stroke and chronic seizures) abnormalities or diseases * Has had mastitis within 30 days prior to administration of study drug